ALVIO Stock Overview
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.11 |
52 Week High | €0.39 |
52 Week Low | €0.09 |
Beta | 1.64 |
1 Month Change | -9.17% |
3 Month Change | -33.94% |
1 Year Change | -64.20% |
3 Year Change | -84.88% |
5 Year Change | -86.54% |
Change since IPO | -99.18% |
Recent News & Updates
Recent updates
Shareholder Returns
ALVIO | FR Biotechs | FR Market | |
---|---|---|---|
7D | 9.2% | 1.0% | 0.4% |
1Y | -64.2% | -1.8% | 9.6% |
Return vs Industry: ALVIO underperformed the French Biotechs industry which returned -1.8% over the past year.
Return vs Market: ALVIO underperformed the French Market which returned 9.6% over the past year.
Price Volatility
ALVIO volatility | |
---|---|
ALVIO Average Weekly Movement | 8.3% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.2% |
10% most volatile stocks in FR Market | 9.8% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALVIO's share price has been volatile over the past 3 months.
Volatility Over Time: ALVIO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 39 | Shefali Agarwal | https://valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Valerio Therapeutics Société anonyme Fundamentals Summary
ALVIO fundamental statistics | |
---|---|
Market cap | €16.79m |
Earnings (TTM) | -€19.73m |
Revenue (TTM) | €1.44m |
11.6x
P/S Ratio-0.9x
P/E RatioIs ALVIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALVIO income statement (TTM) | |
---|---|
Revenue | €1.44m |
Cost of Revenue | €491.00k |
Gross Profit | €952.00k |
Other Expenses | €20.69m |
Earnings | -€19.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 65.97% |
Net Profit Margin | -1,367.64% |
Debt/Equity Ratio | 55.3% |
How did ALVIO perform over the long term?
See historical performance and comparison